NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-
testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit …

New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA)
family, and has been identified as one of the most immunogenic tumor-associated antigens …

Abstract Introduction Cancer Immunotherapy has recently emerged as a promising and
effective modality to treat different malignancies. Antigenic profiling of cancer tissues and …

Since the early 1990s, numerous cancer Ag have been defined and for a handful of these
there is now some clinical experience, which has made it possible to assess their value as …

In the 9 years since its discovery, cancer‐testis antigen NY‐ESO‐1 has made one of the
fastest transitions from molecular, cellular, and immunological description to vaccine and …

Harnessing the immune system to eradicate malignant cells is becoming a most powerful
new approach to cancer therapy. FDA approval of the immunotherapy-based drugs …

The NY-ESO-1 gene product is expressed by a range of human tumors and is recognized by
antibodies from sera of cancer patients with NY-ESO-1-expressing tumors. The NY-ESO-1 …

Tumour associated antigens recognised by cellular or humoral effectors of the immune
system are potential targets for antigen specific cancer immunotherapy. Different categories …

Abstract NY-ESO-1 is a 180 amino-acid human tumor antigen expressed by many different
tumor types and belongs to the family of “cancer-testis” antigens. In humans, NY-ESO-1 is …

NY-ESO-1 is a member of the cancer-testis family of tumor antigens that elicits strong
humoral and cellular immune responses in patients with NY-ESO-1–expressing cancers …